AbbVie Inc, founded in 2013 and headquartered in North Chicago, Illinois, is a global biopharmaceutical company dedicated to the development and commercialization of innovative therapies. The company focuses on various therapeutic areas, including immunology, oncology, neuroscience, and virology, with flagship products such as Humira and Imbruvica contributing significantly to its portfolio.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
AbbVie began actively issuing corporate bonds shortly after its spinoff from Abbott Laboratories in 2013. Notable issuances include a $30 billion bond offering in 2020, which was utilized to finance the acquisition of Allergan, significantly expanding its product offerings and market reach. As of 2023, AbbVie's bond yields remain competitive with the industry, reflecting solid credit ratings. The company’s bonds exhibit features such as call provisions, providing flexibility in refinancing during favorable market conditions.